Scientists at the MRC Laboratory of Medical Sciences (LMS) have discovered a DNA-based “dimmer switch” that regulates the activity of a critical developmental gene, Cdx2. This work could pave the way ...

NEW YORK, April 02, 2025--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare ...

For decades, synthetic biologists have been developing gene circuits that can be transferred into cells for applications such as reprogramming a stem cell into a neuron or generating a protein that ...

NEW YORK - Neurogene Inc. (NASDAQ: NGNE), a clinical-stage biotech company currently valued at $156 million, has announced the publication of a study in Science Translational Medicine detailing its ...